ChronoScale AI Stock Analysis
Want to see CHRN full AI Analyst Report?
ChronoScale (CHRN) AI Stock Analysis
ChronoScale
(NASDAQ:CHRN)
The score is held down primarily by weak fundamentals (deep losses and higher leverage despite strong revenue growth) and clearly bearish technicals (below all major moving averages with negative MACD). Offsetting factors are the recent shift to positive operating/free cash flow and several positive corporate events strengthening the contracted AI infrastructure pipeline, but valuation cannot be supported with missing P/E and dividend yield data.
ChronoScale Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales across regions (U.S., Europe, Asia, etc.), showing where Ekso Bionics depends on demand, reimbursement rules, and local distribution partners. High concentration in a single region raises regulatory, reimbursement, or market risk; broader geographic mix signals more adoption, growth runway, and resilience to localized slowdowns.
EKSO remains heavily dependent on Americas revenue, which drives large quarter-to-quarter swings and creates pronounced earnings volatility; EMEA emerged as a meaningful growth lane through 2024 but pulled back in 2025, undermining diversification gains. APAC is small and erratic—occasional upside but not a reliable contributor. Absent steadier international traction or clearer order/backlog visibility, continued reliance on lumpy Americas demand is the primary execution risk for near‑term revenue consistency.
ChronoScale (CHRN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $34.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 148.08K
- Price to Earnings (P/E)
- ―
- Beta (1Y)
- 1.57
- Revenue Growth
- 190.16%
- EPS Growth
- 50.07%
- Country
- US
- Employees
- 86
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Information Technology Services
ChronoScale Business Overview & Revenue Model
Company Description
ChronoScale Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, and...
ChronoScale Earnings Call Summary
The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.
ChronoScale Financial Statement Overview
Summary
Revenue growth is extremely strong (~341% TTM) with gross margin holding near ~53% and cash flow has turned positive (OCF ~6.1M; FCF ~3.0M). However, profitability is still very weak (net margin about -136%) with losses expanding, leverage has stepped up (debt-to-equity ~0.75), and KPI insights point to a less resilient/recurring revenue mix and uneven regional execution.
Income Statement
22NegativeBalance Sheet
40NegativeCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.99M | 12.80M | 17.93M | 18.28M | 12.91M | 11.25M |
| Gross Profit | 1.15M | 6.84M | 9.51M | 9.08M | 6.21M | 6.75M |
| EBITDA | -20.61M | -9.81M | -9.45M | -13.20M | -14.04M | -9.09M |
| Net Income | -55.46M | -11.70M | -11.33M | -15.20M | -15.08M | -9.76M |
Balance Sheet | ||||||
| Total Assets | 295.40M | 20.11M | 26.65M | 28.92M | 40.90M | 49.17M |
| Cash, Cash Equivalents and Short-Term Investments | 15.22M | 1.17M | 6.49M | 8.64M | 20.52M | 40.41M |
| Total Debt | 111.06M | 2.64M | 5.98M | 7.17M | 7.50M | 2.22M |
| Total Liabilities | 144.75M | 11.08M | 13.95M | 16.31M | 15.46M | 11.95M |
| Stockholders Equity | 150.65M | 9.03M | 12.71M | 12.61M | 25.44M | 37.22M |
Cash Flow | ||||||
| Free Cash Flow | 3.05M | -11.99M | -9.88M | -12.21M | -14.88M | -11.21M |
| Operating Cash Flow | 6.11M | -11.80M | -9.85M | -12.05M | -14.69M | -11.16M |
| Investing Cash Flow | -3.20M | -188.00K | -37.00K | -157.00K | -5.17M | -59.00K |
| Financing Cash Flow | 1.43M | 6.63M | 7.77M | 348.00K | 0 | 38.71M |
ChronoScale Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRN, the sentiment is Negative. The current price of 9.74 is below the 20-day moving average (MA) of 13.28, below the 50-day MA of 16.62, and below the 200-day MA of 16.18, indicating a bearish trend. The MACD of -1.98 indicates Positive momentum. The RSI at 32.15 is Neutral, neither overbought nor oversold. The STOCH value of 10.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CHRN.
ChronoScale Risk Analysis
ChronoScale disclosed 60 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksChronoScale Peers Comparison
Overall Rating
HBIO52Neutral
CHRN46Neutral
MLSS44Neutral
LUCY42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| 52Neutral | $41.52M | -3.53 | -130.06% | ― | 2.34% | 78.52% | |
| 46Neutral | $1.42B | ― | 0.00% | ― | 190.16% | 50.07% | |
| 44Neutral | $25.10M | -6.67 | -122.29% | ― | 3.93% | 48.18% | |
| 42Neutral | $6.73M | -0.64 | -102.66% | ― | 56.89% | 52.61% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CHRN | Chronoscale Corporation | 9.74 | 5.71 | 141.69% | |
| HBIO | Harvard Bioscience | 9.08 | 2.88 | 46.52% | |
| MLSS | Milestone Scientific Inc | 0.28 | -0.04 | -13.44% | |
| LUCY | Innovative Eyewear, Inc. | 0.77 | -0.83 | -51.75% |
ChronoScale Corporate Events
ChronoScale Holdings Reports Results of Annual Stockholder Meeting
NeutralOn November 6, 2026, ChronoScale Holdings Corporation held its annual meeting of stockholders. Stockholders elected Wes Cummins, Ella Benson, Ying Cenly Chen, William M. Clancy, Douglas Miller, Richard Nottenburg and Andrew Schaap as directors to ser...
ChronoScale Director Resigns Following Ekso Bionics Divestiture
NeutralChronoScale Holdings Corporation reported that in connection with the sale of its wholly owned subsidiary Ekso Bionics, Inc. completed on September 30, 2026, Scott Davis resigned from the company’s board of directors effective October 3, 2026, while...
ChronoScale expands AI infrastructure contracts, refines growth focus
PositiveChronoScale completed the sale of its Ekso Bionics business unit on September 30, 2026, and subsequently terminated Ekso’s Chief Operating Officer, Jason C. Jones, on the same date, with Ekso entering into a severance and release agreement granting h...
ChronoScale amends term loan, extends debt maturity
PositiveOn September 12, 2026, ChronoScale Intermediate, LLC and Ekso Bionics, Inc. amended their existing $2.0 million secured term loan agreement with B. Riley Commercial Capital, LLC, under which the full principal amount remained outstanding at the time...
ChronoScale, Microsoft expand AI infrastructure partnership deployment
PositiveOn August 27, 2026, ChronoScale announced a strategic partnership with Microsoft to develop a 50-megawatt AI compute deployment in North America, integrating NVIDIA GB300 NVL72 systems and advanced liquid-cooling infrastructure. The project is design...
ChronoScale confirms CFO role with new compensation package
PositiveOn August 16, 2026, ChronoScale Corporation entered into an Offer of Continued Employment and a Covenants Agreement with Chief Financial Officer Jerome Wong, confirming his role and setting his annual base salary at $400,000 with a target performance...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
